Tau tracers have been tested in clinical settings in several neurodegenerative diseases, including classic AD and atypical AD presentations, PSP, FTD, CTE, etc. However, the studies regarding Tau PET tracers in primary tauopathies and dementia are still ongoing. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.